Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine

被引：0
|
作者：
Janne T. Backman
Marika T. Schröder
Pertti J. Neuvonen
机构：
[1] University of Helsinki and Helsinki University Central Hospital,Department of Clinical Pharmacology
[2] University of Helsinki,Department of Clinical Pharmacology
来源：
European Journal of Clinical Pharmacology | 2008年 / 64卷
关键词：
Gender; Smoking; Tizanidine; CYP1A2; Caffeine test;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：17 / 24
页数：7
相关论文
共 50 条
  • [31] Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans
    Becquemont, L
    Ragueneau, I
    LeBot, MA
    Riche, C
    FunckBrentano, C
    Jaillon, P
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (06) : 619 - 627
  • [32] CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy
    Djordjevic, Natasa
    Milovanovic, Dragana Dragas
    Radovanovic, Marija
    Radosavljevic, Ivan
    Obradovic, Slobodan
    Jakovljevic, Mihajlo
    Milovanovic, Dragan
    Milovanovic, Jasmina R.
    Jankovic, Slobodan
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (04) : 439 - 445
  • [33] CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy
    Natasa Djordjevic
    Dragana Dragas Milovanovic
    Marija Radovanovic
    Ivan Radosavljevic
    Slobodan Obradovic
    Mihajlo Jakovljevic
    Dragan Milovanovic
    Jasmina R. Milovanovic
    Slobodan Jankovic
    European Journal of Clinical Pharmacology, 2016, 72 : 439 - 445
  • [34] Smoking impact on CYP1A2 activity in a group of patients with schizophrenia
    Bozikas, VP
    Papakosta, M
    Niopas, L
    Karavatos, A
    Mirtsou-Fidani, V
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 (01) : 39 - 44
  • [35] Smoking and tardive dyskinesia:: lack of involvement of the CYP1A2 gene
    Chong, SA
    Tan, EC
    Tan, CH
    Mythily
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 2003, 28 (03): : 185 - 189
  • [36] Prediction of inter-individual variability on the pharmacokinetics of CYP1A2 substrates in non-smoking healthy volunteers
    Haraya, Kenta
    Kato, Motohiro
    Chiba, Koji
    Sugiyama, Yuichi
    DRUG METABOLISM AND PHARMACOKINETICS, 2016, 31 (04) : 276 - 284
  • [37] Selective inhibitory effects of mollugin on CYP1A2 in human liver microsomes
    Kim, Heeyeon
    Choi, Hyun Kyu
    Jeong, Tae Cheon
    Jahng, Yurngdong
    Kim, Dong Hyun
    Lee, Seung-Ho
    Lee, Sangkyu
    FOOD AND CHEMICAL TOXICOLOGY, 2013, 51 : 33 - 37
  • [38] Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2
    Scherf-Clavel, Maike
    Samanski, Lydia
    Hommers, Leif G.
    Deckert, Juergen
    Menke, Andreas
    Unterecker, Stefan
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2019, 34 (02) : 93 - 100
  • [39] Selective inhibitory effects of suberosin on CYP1A2 in human liver microsomes
    Paudel, Sanjita
    Jo, Hyoje
    Lee, Taeho
    Lee, Sangkyu
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2023, 44 (05) : 365 - 371
  • [40] Effects of Baicalin on Pharmacokinetics of Florfenicol and mRNA Expression of CYP1A2, CYP2C11, CYP3A1, UGT1A1, MDR1, and ABCC2 in Rats
    Li, Si-Cong
    Li, Xu-Ting
    Wang, Bin
    Yang, Rui
    Zhang, Min
    Li, Jin-Liang
    Huang, Wei
    Cao, Liang
    Xiao, Song-Yang
    PHARMACOGNOSY MAGAZINE, 2020, 16 (67) : 1 - 6
12345